The CLDX news and ASH results are a strong indication that SGEN is making the right moves. CD-30 expression is a great niche and along with others on this message board believe that with the multiple methods of generating revenue that SGEN will make a steady climb.
Of course the interim factors could be the fiscal cliff, so I am glad that Congress isn't running the company. Any comments on how good the results that CLDX revealed are?
Bodes well for both SGEN and CLDX. I think that at this point SGEN gets more of the benefit because pharma is looking for options to expand its pipeline and SGEN ADCs are proving to be a method of getting there as the validation grows.
Interesting where SGEN will make its money in the future, licensing its platform or its own drug development or royalties from partners.
Any convincingly positive "proof of concept" clinical trial data surrounding the treatment of chemo resistant solid tumors is a potential strong buttress towards broadening this particular brand of ADC platform technology.
Good for SGEN, good for CLDX and potentially GREAT for patients.